Aclarion, Inc. (ACON)

NCM – Real vaqt narxi. Valyuta: USD

3.15

+0.05 (1.61%)

Yopilishda: May 12, 2026, 4:00 PM EDT

11.05.2026

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

“Matching the right procedure to the right patient is what moves the field forward” BROOMFIELD, Colo., May 07, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.

07.05.2026

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

“Matching the right procedure to the right patient is what moves the field forward” Lanman Spinal Neurosurgery is a leading spine-focused private practice recognized for its expertise in complex spinal procedures, early adoption of innovative technologies and high surgical volume The CLARITY randomized clinical trial is designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain BROOMFIELD, Colo., May 07, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of Lanman Spinal Neurosurgery as a clinical site in its CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial.

06.05.2026

Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.

BROOMFIELD, Colo., May 06, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that the compensation committee of Aclarion's board of directors granted Daniel Keefe, the Company's recently-hired Commercial Director, Western U.S., an inducement stock option to purchase an aggregate of 17,000 shares of Aclarion's common stock on May 5, 2026.

05.05.2026

Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine

BROOMFIELD, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, announced today it has established a second commercial agreement with Weill Cornell Medicine.

30.04.2026

Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption

Triple-digit annual growth signals accelerating Nociscan adoption and integration into clinical workflows Advancing reimbursement and clinical milestones, with CLARITY trial interim readout anticipated in Q4 2026 Strengthened IP footprint with new AI patent and 64 total issued and pending patents worldwide Announced $2.5 million share repurchase program Strong balance sheet, no debt and cash runway into the second half of 2027, reinforcing long-term growth strategy BROOMFIELD, Colo., April 30, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today reported first quarter 2026 results highlighted by accelerating clinical adoption and strong execution across key strategic initiatives.

28.04.2026

Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan

Commercial leader with proven track record of driving growth, surgeon adoption, and market expansion with innovative spine and surgical technologies Expansion of commercial team reflects increasing demand for Nociscan, supported by triple-digit growth in utilization BROOMFIELD, Colo., April 28, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the appointment of Daniel Keefe as Commercial Director, Western U.S. Dan will lead commercial efforts across the Western region, building on Aclarion's existing footprint and supporting continued adoption of Nociscan.

24.04.2026

PRISM MediaWire – Weekly Press Release Round Up – April 20 to April 24, 2026 – Top Financial & Corporate News Highlights

$AERA $BCBC $ACON $SKYX $AUUD $SSII $BIEI $ATCH PRISM MarketViev About PRISM MediaWire PRISM MediaWire is a New York City–based press release distribution company specializing in capital markets communications for publicly traded companies.

Videolar

No Data

There is no data to display

Press-relizlar

11.05.2026

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

07.05.2026

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

06.05.2026

Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.

05.05.2026

Aclarion, Inc. (ACON)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Aclarion, Inc. (ACON)

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.

Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine

Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption

Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan

PRISM MediaWire – Weekly Press Release Round Up – April 20 to April 24, 2026 – Top Financial & Corporate News Highlights

Videolar

No Data

Press-relizlar

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.

Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.

Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine

Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption

Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan

PRISM MediaWire – Weekly Press Release Round Up – April 20 to April 24, 2026 – Top Financial & Corporate News Highlights

Videolar

No Data

Press-relizlar

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.

Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine

Search stocks

Aclarion, Inc. (ACON)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Aclarion, Inc. (ACON)

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.

Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine

Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption

Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan

PRISM MediaWire – Weekly Press Release Round Up – April 20 to April 24, 2026 – Top Financial & Corporate News Highlights

Videolar

No Data

Press-relizlar

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.

Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.

Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine

Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption

Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan

PRISM MediaWire – Weekly Press Release Round Up – April 20 to April 24, 2026 – Top Financial & Corporate News Highlights

Videolar

No Data

Press-relizlar

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.

Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine